Results 91 to 100 of about 10,664 (186)

Antiinflammatory therapy with canakinumab for atherosclerotic disease

, 2017
Antiinflammatory therapy with canakinumab for atherosclerotic ...
D Pella (11509027), L Salvador (18763891), T Ponce (18763972), T Perlstein (18763936), J Nicolau (18763846), R Cifkova (13338225), J Varigos (13417008), A Fucili (18763885), S Chou (13525051), B Charmarthi (18763924), KB Seung (18763903), H Rugo (16127177), AP Limaye (18763954), W Koenig (7606655), T Forster (14479485), T Mayer (13445757), H Kultursay (18763909), M Tan (7805873), WH Chang (5161220), AJ Manolis (18763879), M Lainscak (18763900), P Commerford (13445004), S Bilazarian (18763912), D Milicic (18763873), J Danik (18763927), J Scott (6806273), P Pais (8718459), M Flather (8412135), C Ballantyne (7812800), S Cosgrove (16086515), D Levine (9097031), B Olenchock (18763933), B Harris (13312794), E Bohula (18763921), A Singhal (7792781), P Sinnaeve (13416603), JJ Hwang (15863678), P Libby (18763867), P Otasevic (18763897), A Budaj (13415211), H Ogawa (16121285), R Hilkert (18763957), JJP Kastelein (14548829), M Urina-Triana (13415835), BM Everett (7696601), J Woelcke (18763966), A Cioffi (18763942), K Banker (18698611), G Tamesby (18763960), V Taqueti (18763939), P Siostrzonek (13317897), M Ning (16333413), N Rost (13416315), H Yong (13294725), R Saini (18763975), RPT Troquay (18763864), H Burris (8472489), R Lopes (15834425), I Veze (18763888), C East (12276503), AM Dalseg (18763945), B Manning (13472398), A Lorenzatti (13555945), PRF Rossi (18763861), N Ghosh (18763948), T Thuren (18763837), B Maron (18763930), H Shimokawa (18763858), B Petrauskiene (13554013), M Ligueros (18763918), JG MacFadyen (18763840), L Forgosh (18763915), H Krum (13358178), N Wei (16102727), T Salko (18763978), R Vettus (18763876), N Gotcheva (18763870), F Wyss (18763882), PM Ridker (7696604), TO Klemsdal (18763894), J Kam (13407507), L Vida-Simiti (18763855), RJ Glynn (15863651), M Dellborg (13539124), F Fonseca (18763843), S Cheng (7552271), V Fowler (13517167), SD Anker (7731083), Z Kobalava (18763852), JH Cornel (15898946), M Donath (18763906), R Pande (7764311), S Manfreda (18763969), C Mickel (18763963), A Sigurdsson (7634621), A Pradhan (13329864), J Gralow (18763951), G McMahon (7706441), J Genest (18763849), F Medina (7816628)   +99 more
core  

The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells.

PLoS ONE
Muscle inflammation is one of the hallmarks of Duchenne muscular dystrophy (DMD). Dystrophin-deficient skeletal muscle cells produce higher levels of pro-inflammatory cytokines such as interleukin 1β (IL-1β) in response to toll-like receptor stimulation ...
Anna Cordeiro-Santanach, Fiorella Morales, Maria Del Carmen Parquet, Kitipong Uaesoontrachoon, Joyce Rowsell, Jordan Warford, Wilson Wu, Pia Elustondo, Eric P Hoffman, Kanneboyina Nagaraju   +9 more
doaj   +1 more source

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)

Pharmaceuticals
Background: Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential.
Weidong Zhang, Yunzhou Chen, Zeyu Yao, Mengling Ouyang, Minghui Sun, Shupeng Zou   +5 more
doaj   +1 more source

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1327-1338, June 2026.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna De Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Programmed Cell Death in Chronic Rhinosinusitis

Clinical and Translational Allergy, Volume 16, Issue 6, June 2026.
ABSTRACT Chronic rhinosinusitis (CRS) is a prevalent upper respiratory condition characterized by a multifaceted etiology involving various cellular and molecular processes. In recent years, researchers have increasingly recognized the significance of different forms of programmed cell death (PCD), such as apoptosis and pyroptosis, in the pathological ...
Xingchen Liu, Junying Hu, Weigang Gan, Qi Wu, Bing Zhong, Feng Liu   +5 more
wiley   +1 more source

Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system

Frontiers in Pharmacology
BackgroundAnakinra and canakinumab are two FDA-approved IL-1 blockers indicated for the treatment of multiple autoinflammatory diseases, yet their safety has not been comprehensively analyzed.
Hao Liu, Wei Yan, Jinsong Li, Dezhi Yan, Di Luo   +4 more
doaj   +1 more source

Possible chondroprotective effect of canakinumab: an in vitro study on human osteoarthritic chondrocytes.

, 2015
Canakinumab is a human IgGκ monoclonal antibody that neutralizes the activity of interleukin (IL)-1β blocking interaction with IL-1β receptors. Our study aimed to evaluate the in vitro effect of canakinumab on human osteoarthritic (OA) chondrocytes ...
Pascarelli NA, CANTARINI, LUCA, CHELESCHI, SARA, GALEAZZI, MAURO, Nicola Antonio Pascarelli, Orso Maria Lucherini, Sara Cheleschi, LUCHERINI, ORSO MARIA, COLLODEL, GIULIA, Antonella Fioravanti, Fioravanti A., Mauro Galeazzi, Luca Cantarini, Giulia Collodel   +13 more
core   +1 more source

Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review

, 2020
BACKGROUND: Schnitzler syndrome is a rare autoinflammatory disorder characterized by chronic urticarial rash and a monoclonal gammopathy, accompanied by intermittent fever, bone pain, and arthralgia or arthritis.
Staels, F., Betrains, A., Vanderschueren, S.   +2 more
core   +1 more source

Towards a cure for gout: A two‑stage treat‐to‐target strategy from inflammation control to structural remission

Rheumatology &Autoimmunity, EarlyView.
Jiani Liu, Ziwen Xu, Wenxi Cui, Man Lu, Qingqing Zhang, Wenxia Lin, Shixian Chen, Weikai Lin, Guichuan Lai, Meng Li, Juan Li   +10 more
wiley   +1 more source

Experience of the successful treatment with canakinumab of a patient with NLPC4-associated autoinflammatory syndrome with enterocolitis

Педиатрическая фармакология, 2016
The article shows the observation of rare NLPC4-associated autoinflammatory syndrome with enterocolitis and familial cold urticaria. Diagnosis is confirmed molecularly-genetically: previously not described mutation c.928C>T in the heterozygous state ...
T. V. Sleptsova, E. I. Alexeeva, K. V. Savost’yanov, A. A. Pushkov, T. M. Bzarova, S. I. Valieva, O. L. Lomakina, R. V. Denisova, K. B. Isaeva, E. G. Chistyakova   +9 more
doaj   +1 more source